Compare ASTRAZENECA PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FRESENIUS KABI ONCO. ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 122.5 22.1 553.4% View Chart
P/BV x 35.8 3.1 1,150.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,278176 726.1%   
Low Rs88379 1,124.3%   
Sales per share (Unadj.) Rs228.437.7 606.1%  
Earnings per share (Unadj.) Rs10.45.1 203.5%  
Cash flow per share (Unadj.) Rs16.36.7 241.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.842.5 232.2%  
Shares outstanding (eoy) m25.00158.23 15.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.4 140.1%   
Avg P/E ratio x104.225.0 417.2%  
P/CF ratio (eoy) x66.418.9 351.0%  
Price / Book Value ratio x10.93.0 365.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,00820,135 134.1%   
No. of employees `0001.41.2 117.7%   
Total wages/salary Rs m1,535703 218.3%   
Avg. sales/employee Rs Th4,210.95,176.2 81.4%   
Avg. wages/employee Rs Th1,132.2610.4 185.5%   
Avg. net profit/employee Rs Th191.1699.6 27.3%   
INCOME DATA
Net Sales Rs m5,7105,963 95.8%  
Other income Rs m12318 680.6%   
Total revenues Rs m5,8335,981 97.5%   
Gross profit Rs m4631,430 32.4%  
Depreciation Rs m147258 57.2%   
Interest Rs m0-26 0.0%   
Profit before tax Rs m4381,216 36.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m179342 52.3%   
Profit after tax Rs m259806 32.2%  
Gross profit margin %8.124.0 33.8%  
Effective tax rate %40.828.1 145.2%   
Net profit margin %4.513.5 33.6%  
BALANCE SHEET DATA
Current assets Rs m3,2095,102 62.9%   
Current liabilities Rs m2,0702,385 86.8%   
Net working cap to sales %20.045.6 43.8%  
Current ratio x1.62.1 72.5%  
Inventory Days Days72150 48.2%  
Debtors Days Days35113 30.8%  
Net fixed assets Rs m7905,148 15.4%   
Share capital Rs m50158 31.6%   
"Free" reserves Rs m2,4196,556 36.9%   
Net worth Rs m2,4696,732 36.7%   
Long term debt Rs m0952 0.0%   
Total assets Rs m4,60510,388 44.3%  
Interest coverage xNM-45.8-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.20.6 216.0%   
Return on assets %5.67.5 74.9%  
Return on equity %10.512.0 87.6%  
Return on capital %17.714.6 121.5%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m3005,298 5.7%   
Fx outflow Rs m2,0151,772 113.7%   
Net fx Rs m-1,7153,525 -48.7%   
CASH FLOW
From Operations Rs m881,274 6.9%  
From Investments Rs m-94-1,204 7.8%  
From Financial Activity Rs mNA-196 0.0%  
Net Cashflow Rs m-6-126 4.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 15.7 9.6 163.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   12,856 42,599 30.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 466 Points Higher; Energy, Auto and Realty Stocks Rally(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note, driven by automobile stocks and index heavyweight Reliance Industries.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 6, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS